Popular Trials
Monoclonal Antibodies
Ocrelizumab for Psychosis
This trial is investigating whether some people diagnosed with schizophrenia or bipolar disorder may actually have a brain disease caused by auto-antibodies. These auto-antibodies attack brain receptors, leading to symptoms
Procedure
Stem Cell Transplant for Autoimmune Diseases
This trial is testing a new treatment strategy for children and young adults with autoimmune diseases that are unresponsive to conventional treatments. The new treatment involves delivering high doses of immunosuppressive therapy followed by an autologous stem cell transplant (ASCT). The goal is to purge the pathogenic, autoreactive immune system and reset the immune system.
CAR T-cell Therapy
Cell Depletion using CliniMACS for Primary Immunodeficiencies
This trial is testing a new way to do a stem cell transplant using cells from either an unrelated or partially matched related donor. There are two different ways to do the transplant depending on the patient's diagnosis and age.
Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
Popular Filters
Trials for Multiple Sclerosis Patients
Anti-bacterial
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Nonsteroidal Anti-inflammatory Drug
Naproxen Sodium for OCD in PANDAS
This trial tests Naproxen Sodium, an anti-inflammatory drug, to see if it can reduce OCD symptoms in children with PANDAS. These children have OCD symptoms linked to inflammation from streptococcal infections. The medication aims to lower inflammation, potentially easing their symptoms.
Trials for Myasthenia Gravis Patients
Anti-bacterial
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Alkylating agents
Stem Cell Transplant for Autoimmune Neurological Diseases
This trial tests a combination of strong chemotherapy and an immune-suppressing medicine followed by a stem cell transplant. It targets patients with autoimmune neurological diseases that haven't improved with other treatments. The treatment aims to weaken the immune system to stop it from attacking the nervous system and then helps the body recover by making new blood cells. High-dose chemotherapy followed by a stem cell transplant has been shown to improve various autoimmune diseases.
Nonsteroidal Anti-inflammatory Drug
Naproxen Sodium for OCD in PANDAS
This trial tests Naproxen Sodium, an anti-inflammatory drug, to see if it can reduce OCD symptoms in children with PANDAS. These children have OCD symptoms linked to inflammation from streptococcal infections. The medication aims to lower inflammation, potentially easing their symptoms.
Trials With No Placebo
Anti-bacterial
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Alkylating agents
Stem Cell Transplant for Autoimmune Neurological Diseases
This trial tests a combination of strong chemotherapy and an immune-suppressing medicine followed by a stem cell transplant. It targets patients with autoimmune neurological diseases that haven't improved with other treatments. The treatment aims to weaken the immune system to stop it from attacking the nervous system and then helps the body recover by making new blood cells. High-dose chemotherapy followed by a stem cell transplant has been shown to improve various autoimmune diseases.
View More Related Trials
Frequently Asked Questions
Introduction to pandas
What are the top hospitals conducting pandas research?
When it comes to pioneering clinical trials for pandas (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections), several top hospitals are leading the way. Massachusetts General Hospital in Boston is at the forefront of research, currently conducting three active panda trials. Similarly, the Hospital for Special Surgery in New york is making significant strides with three ongoing clinical studies focused on this condition. Yale University in New Haven and Cleveland Clinic in Cleveland both have two active panda trials underway, contributing to the growing body of knowledge surrounding this complex disorder. Mayo Clinic in Rochester also joins these esteemed institutions with two ongoing panda trials.
Pandas is a unique pediatric neuropsychiatric disorder that typically begins after a streptococcal infection, such as strep throat or scarlet fever. It involves sudden-onset obsessive-compulsive symptoms, motor tics, anxiety, and other behavioral changes that can be debilitating for affected children and their families. The lack of completed pandas trials thus far highlights both the complexity of the condition and the pressing need for further research.
By conducting these cutting-edge clinical trials, these hospitals are dedicated to unraveling the mysteries of pandas and developing more effective treatment options for affected children. Their efforts not only offer hope to families dealing with this challenging condition but also contribute significantly to medical advancements worldwide
Which are the best cities for pandas clinical trials?
When it comes to pandas clinical trials, several cities emerge as prominent hubs for research and development. Boston, Massachusetts leads the pack with 10 active trials exploring a range of treatments like Cohort B, Arm B2P: BNT162b2, Nivolumab, and Naproxen Sodium. New york City follows closely behind with 10 ongoing studies focusing on interventions such as Nivolumab and Cohort B. Saint Louis, Missouri also plays a significant role in pandas clinical trials with 8 active studies investigating treatments like Molgramostim and Peresolimab. Philadelphia, Pennsylvania contributes to the field with 6 trials studying various interventions including Oral Ifetroban. Lastly, Baltimore, Maryland conducts 5 active trials focusing on therapeutics like Nivolumab and Molgramostim. These cities serve as vital centers for pandas clinical research offering potential breakthroughs in care for patients seeking improved outcomes.
Which are the top treatments for pandas being explored in clinical trials?
In clinical trials, researchers are exploring various treatments for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections). Some of the top treatments being investigated include:
- Intravenous Immunoglobulin (IVIG): Undergoing evaluation in multiple trials
- Antibiotics: Being tested to target and eradicate streptococcus infection
- Cognitive-behavioral therapy (CBT): Investigated as a means to alleviate symptoms and enhance coping strategies.
What are the most recent clinical trials for pandas?
Recent clinical trials offer hope for individuals with pandas, a neuropsychiatric disorder. One promising study explores the use of CD3/CD19 depletion in autologous stem cell transplants, aiming to enhance treatment outcomes. Another trial investigates the efficacy and safety of a 4 mg/kg dose cohort for pandas patients. In addition, researchers are evaluating the potential benefits of VCTX211 unit and J8-K4S2 therapies through phase 1 and phase 2 studies. Furthermore, peresolimab is being investigated in a phase 2 trial to assess its effectiveness against pandas symptoms. These ongoing trials represent significant advancements towards improving the lives of those affected by this condition.
What pandas clinical trials were recently completed?
I'm sorry, but I cannot provide an accurate answer to your question as there is no information about any recently completed clinical trials specifically focused on pandas. Pandas, or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections, is a complex condition that primarily affects children. While research and studies are ongoing to better understand and treat this disorder, it appears that there haven't been any recent clinical trials directly addressing pandas.